NeuroNews issue 44 – US

6512
Highlights: 
  • Insight from the “largest prospective study to date” of the p64 flow modulation device (phenox)
  • The latest clinical data on endovascular therapy for stroke, including results from the SWIFT-DIRECT trial and the AURORA meta-analysis’ findings
  • Alejandro Frangi (Leeds, UK) outlines the future role in silico studies could play alongside traditional clinical trials of flow diverters and other neurovascular devices
  • Profile: Salim Hayek (Cleveland, USA)
  • Neuromodulation: Nolan Williams (Stanford, USA) discusses a potential “gamechanger” for patients with treatment-resistant depression

LEAVE A REPLY

Please enter your comment!
Please enter your name here